Cindy H. Lee

North Terrace
Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic.

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic.

Journal: Frontiers in digital health

Published: December 19, 2025

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Journal: Expert review of hematology

Published: October 13, 2025

Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile.

Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile.

Journal: British journal of haematology

Published: September 02, 2025

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Journal: Internal medicine journal

Published: August 27, 2025

Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia.

Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia.

Journal: Internal medicine journal

Published: February 03, 2025

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.

Journal: Frontiers in oncology

Published: November 28, 2024

A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study.

A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study.

Journal: BMC cancer

Published: November 19, 2024

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: June 12, 2024

Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.

Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.

Journal: Leukemia

Published: June 05, 2024

Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study.

Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study.

Journal: Biomedicines

Published: November 07, 2023

Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.

Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.

Journal: Blood advances

Published: October 11, 2022

Showing 1-12 of 49

Last Updated: 09/26/2026